​

Keros Therapeutics (KROS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

KROS Stock Forecast

Keros Therapeutics (KROS) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $103.50, with a high of $107.00 and a low of $100.00. This represents a 664.97% increase from the last price of $13.53.

$10 $30 $50 $70 $90 $110 High: $107 Avg: $103.5 Low: $100 Last Closed Price: $13.53

KROS Stock Rating

Keros Therapeutics stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (60.00%), 6 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 15 0 6 9 Strong Sell Sell Hold Buy Strong Buy

KROS Price Target Upside V Benchmarks

TypeNameUpside
StockKeros Therapeutics664.97%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$102.00
Last Closing Price$13.53$13.53$13.53
Upside/Downside--653.88%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25265--13
Mar, 25365--14
Feb, 25365--14
Jan, 25385--16
Dec, 243123--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Kelly ShiJefferies$107.00$62.0272.52%690.84%
Nov 05, 2024Srikripa DevarakondaTruist Financial$100.00$62.0261.24%639.10%
Sep 23, 2024Vamil DivanGuggenheim$96.00$55.8072.04%609.53%
Jun 18, 2024Joseph CatanzaroPiper Sandler$105.00$44.65135.16%676.05%
Dec 13, 2022BTIG$105.00$49.98110.08%676.05%
Jul 27, 2022Julian HarrisonBTIG$80.00$31.79151.65%491.28%
May 18, 2022Joseph CatanzaroPiper Sandler$120.00$39.92200.60%786.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 16, 2024GuggenheimBuyNeutraldowngrade
Nov 05, 2024JefferiesBuyinitialise
Oct 24, 2024Cantor FitzgeraldOverweightinitialise
Sep 23, 2024GuggenheimBuyinitialise
Jun 24, 2024OppenheimerOutperforminitialise
Jun 18, 2024Piper SandlerOverweightOverweighthold
Dec 13, 2022BTIGBuyBuyhold
Oct 10, 2022Piper SandlerOverweightOverweighthold
Jul 27, 2022BTIGBuyinitialise

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.52$-4.15$-5.20$-5.00----
Avg Forecast$-3.14$-4.16$-5.24$-5.19$-4.83$-4.36$-4.40$-3.58
High Forecast$-2.78$1.23$-5.11$0.34$-3.18$-2.19$-0.13$1.05
Low Forecast$-4.57$-18.08$-5.38$-6.02$-6.50$-6.76$-7.53$-10.22
Surprise %-19.75%-0.24%-0.76%-3.66%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$20.10M-$151.00K$3.55M----
Avg Forecast$100.00K$1.00M$2.18K$553.33K$3.84M$14.95M$24.33M$78.96M
High Forecast$134.97K$3.57M$5.29K$4.33M$9.31M$36.27M$59.04M$191.57M
Low Forecast$91.23K$4.15K$9.00$10.29K$16.93K$65.95K$107.34K$348.31K
Surprise %20000.00%-6820.26%541.57%----

Net Income Forecast

$-550M $-430M $-310M $-190M $-70M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-58.74M$-104.68M$-152.99M$-187.35M----
Avg Forecast$-92.54M$-122.59M$-152.99M$-83.64M$-140.30M$-190.99M$-200.01M$-105.42M
High Forecast$-81.99M$36.12M$-150.49M$9.99M$-93.51M$-64.46M$-3.83M$31.02M
Low Forecast$-134.60M$-532.53M$-158.43M$-177.28M$-191.40M$-199.11M$-221.81M$-300.86M
Surprise %-36.52%-14.61%-123.99%----

KROS Forecast FAQ

Is Keros Therapeutics stock a buy?

Keros Therapeutics stock has a consensus rating of Buy, based on 15 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Keros Therapeutics is a favorable investment for most analysts.

What is Keros Therapeutics's price target?

Keros Therapeutics's price target, set by 15 Wall Street analysts, averages $103.5 over the next 12 months. The price target range spans from $100 at the low end to $107 at the high end, suggesting a potential 664.97% change from the previous closing price of $13.53.

How does Keros Therapeutics stock forecast compare to its benchmarks?

Keros Therapeutics's stock forecast shows a 664.97% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and outperforming the biotech stocks industry (83.49%).

What is the breakdown of analyst ratings for Keros Therapeutics over the past three months?

  • April 2025: 15.38% Strong Buy, 46.15% Buy, 38.46% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 21.43% Strong Buy, 42.86% Buy, 35.71% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 21.43% Strong Buy, 42.86% Buy, 35.71% Hold, 0% Sell, 0% Strong Sell.

What is Keros Therapeutics’s EPS forecast?

Keros Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-4.83, marking a -3.40% decrease from the reported $-5 in 2024. Estimates for the following years are $-4.36 in 2026, $-4.4 in 2027, and $-3.58 in 2028.

What is Keros Therapeutics’s revenue forecast?

Keros Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.84M, reflecting a 8.10% increase from the reported $3.55M in 2024. The forecast for 2026 is $14.95M, followed by $24.33M for 2027, and $78.96M for 2028.

What is Keros Therapeutics’s net income forecast?

Keros Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-140M, representing a -25.11% decrease from the reported $-187M in 2024. Projections indicate $-191M in 2026, $-200M in 2027, and $-105M in 2028.